This phenomenon may stem from a dual mechanism: low PLR indicates that lymphocyte-mediated anti-tumor immunity is dominant, while the secretion of platelet-derived pro-tumor factors (such as VEGF, TGF-β) is reduced, collectively enhancing the immune activation effect of the dual antibodies (45–47). The gene discussed is TGFB1; the disease is neoplasm.